A Randomized, Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED)
← catalyst calendarSponsored by Viridian Therapeutics, Inc. (industry) · VRDN — their whole pipeline →.
Phase
Phase 3
Status
Completed
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
231actual
Sites
50
Countries
Australia, France, Germany +4
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-05-23 | actual | When the study began enrolling |
| Primary completion | 2025-05-01 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-01-19 | actual | The whole study's end, after follow-up |
| First posted | 2024-04-25 | actual | When this record first appeared on the registry |
| Results posted | 2026-08-13 | actual | When the sponsor posted results to the registry |
| Record updated | 2026-08-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Thyroid Eye Disease
Intervention
- Drug: Veligrotug — also filed as VRDN-001
Primary outcome
what the primary-completion date above is the date OFNumber of Participants With Treatment-emergent Adverse Events (TEAEs) Through Week 15
measured Baseline through Week 15
Posted documents
hosted by the registry — we link, never re-serveStudy Protocolposted 2024-05-06 · 788 KB · Prot_000.pdf
Statistical Analysis Planposted 2026-02-06 · 1.1 MB · SAP_001.pdf
Permalink · VRDN's whole pipeline · Catalyst calendar · Every registered study · What changed